Updates are available Erratum dated 2015-09-10
Click to view Erratum: https://doi.org/10.1038/eye.2015.145
-
Authors
Yang, Y
,
Bailey, C
Holz, F G
Eter, N
Weber, M
Baker, C
Kiss, S
Menchini, U
Ruiz Moreno, J M
Dugel, P
Lotery, A
- License Information
-
More Information
Article History
Received: 1 December 2014
Accepted: 6 May 2015
First Online: 26 June 2015
Change Date: 10 September 2015
Change Type: Correction
Change Details: This article has been corrected since Advance Online Publication and a corrigendum is also printed in this issue
Competing interests
: YY: honoraria, advisory board: Alimera Sciences, Allergan, Alcon, Bayer, Novartis, Thrombogenics; consultancy: Alimera Sciences, Allergan; CB: honoraria: Novartis; commercial funding for clinical trial recruitment via Bristol Eye Hospital: Alimera Sciences; research funding for clinical trials work via Bristol Eye Hospital: Bayer; FGH: research funding, consultancy, grants, honoraria: Alimera Sciences, Allergan, Novartis; NE: research funding, speakers bureau, honoraria, advisory board: Novartis, Bayer, Allergan; speakers bureau, honoraria: Heidelberg Engineering; advisory board: Bausch and Lomb; research funding, advisory board: Alimera Sciences; MW: honoraria, advisory board: Alimera Sciences; CB: advisory board: Alimera Sciences; SK: consultancy, honoraria: Alimera Sciences, Allergan, Genentech/Roche, Regeneron, speakers bureau: Allergan, Genentech/Roche, Regeneron; PD: consultancy, honoraria: Alimera Sciences, Allergan, Alcon; AL: research funding, honoraria, advisory committee: Alimera Sciences; JMRM and UM: nothing to disclose.
